Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
NCT02147925 on ClinicalTrials.gov · last registry update 2018-05-18
Finished April 2017, after enrolling 75 people. Primary outcome, as filed: Intrahepatic lipids (IHL). liraglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Sun Yat-sen University
- Sponsor type
- Other
- Enrollment
- 75
- Started
- 2014-08
- Primary completion
- 2017-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Intrahepatic lipids (IHL)
Conditions studied
Non-alcoholic Fatty Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.